Razoxane

立即咨询

Razoxane

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

21416-67-1

ICRF 159

Razoxane (ICRF 159) 是一种抗血管生成拓扑异构酶 II (topoisomerase II) 抑制剂，可用于肾细胞癌 (RCC) 的研究。

生物活性

Razoxane (ICRF 159) is an antiangiogenictopoisomeraseIIinhibitor, can be used for the research of renal cell carcinoma (RCC)^[1].

IC₅₀& Target^[1]

Topoisomerase II

体外研究
(In Vitro)

Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.

体内研究
(In Vivo)

Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)^[2].

Animal Model:	Sprague-Dawley rats^[2]
Dosage:	30 mg/kg or 10 mg/kg per day
Administration:	Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation
Result:	Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.

分子量

268.27

Formula

C₁₁H₁₆N₄O₄

CAS 号

21416-67-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.